Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 16, Issue 10, Pages 1291-1301
Publisher
Informa UK Limited
Online
2016-08-13
DOI
10.1080/14712598.2016.1221920
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)
- (2016) Niels W.C.J. van de Donk et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
- (2016) Jesus Berdeja et al. Clinical Lymphoma Myeloma & Leukemia
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant
- (2015) Sarah A. Holstein et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)
- (2015) M. Dimopoulos et al. Clinical Lymphoma Myeloma & Leukemia
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I safety data of lenalidomide, bortezomib, dexamethasone and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
- (2015) S Z Usmani et al. Blood Cancer Journal
- Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
- (2015) Paul G Richardson et al. Lancet Haematology
- The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma
- (2014) S. V. Glavey et al. BLOOD
- International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
- (2014) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells
- (2014) Huaijian Guo et al. MOLECULAR AND CELLULAR BIOLOGY
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) P. Moreau et al. ANNALS OF ONCOLOGY
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma
- (2013) Sagar Lonial et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
- (2012) O. J. Finn ANNALS OF ONCOLOGY
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis
- (2011) Jonathan R. Genzen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment
- (2010) Ulrike Klein et al. ANNALS OF HEMATOLOGY
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
- (2010) Meletios Dimopoulos et al. CANCER
- Interference of Monoclonal Antibody Therapies with Serum Protein Electrophoresis Tests
- (2010) C. R. McCudden et al. CLINICAL CHEMISTRY
- Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
- (2009) Benjamin D. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Cancer Immunology
- (2008) Olivera J. Finn NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More